Literature DB >> 15699383

Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease.

D W Tsuang1, R K Wilson, O L Lopez, E K Luedecking-Zimmer, J B Leverenz, S T DeKosky, M I Kamboh, R L Hamilton.   

Abstract

OBJECTIVE: To explore the association between APOE*4 and pathologically confirmed cases of the Lewy body (LB) variant of Alzheimer disease (AD).
METHODS: With use of alpha-synuclein (AS) immunohistochemistry, LBs were detected in 74 of 131 (56.5%) of the AD + LB cases; the remaining 57 cases (43.5%) did not have LBs.
RESULTS: There were no differences in gender or age between Caucasian subjects with AD + LB or AD alone or control subjects. The APOE*4 allele frequency was highest in the AD + LB group (47.3%; 95% CI = 37.8 to 57.0%), intermediate in the AD-alone group (35.1%; 95% CI = 25.3 to 46.3%), and lowest in the control group (14.2%; 95% CI = 10.5 to 18.9%). With use of logistic regression analysis, the odds of having AD + LB vs AD alone were 2.1-fold (95% CI = 1.0 to 4.5, p = 0.055) greater in persons with an APOE*4 allele than in those without an APOE*4 allele.
CONCLUSION: The APOE*4 allele is associated with the presence of concomitant Lewy bodies in Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699383      PMCID: PMC1487185          DOI: 10.1212/01.WNL.0000150892.81839.D1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?

Authors:  Pascal Kurosinski; Mathias Guggisberg; Jürgen Götz
Journal:  Trends Mol Med       Date:  2002-01       Impact factor: 11.951

2.  Parkinson's disease in patients with Alzheimer's disease.

Authors:  J Leverenz; S M Sumi
Journal:  Arch Neurol       Date:  1986-07

3.  Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner.

Authors:  Christopher M Lauderback; Jaroslaw Kanski; Janna M Hackett; Noboyo Maeda; Mark S Kindy; D Allan Butterfield
Journal:  Brain Res       Date:  2002-01-04       Impact factor: 3.252

4.  A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia.

Authors:  F Massoud; G Devi; Y Stern; A Lawton; J E Goldman; Y Liu; S S Chin; R Mayeux
Journal:  Arch Neurol       Date:  1999-11

5.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

Authors:  E Masliah; E Rockenstein; I Veinbergs; Y Sagara; M Mallory; M Hashimoto; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

6.  Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions.

Authors:  V Haroutunian; M Serby; D P Purohit; D P Perl; D Marin; M Lantz; R C Mohs; K L Davis
Journal:  Arch Neurol       Date:  2000-08

7.  Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.

Authors:  A Heyman; G G Fillenbaum; M Gearing; S S Mirra; K A Welsh-Bohmer; B Peterson; C Pieper
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

8.  Dementia with Lewy bodies and Alzheimer's disease.

Authors:  C K Rosenberg; T J Cummings; A M Saunders; C Widico; L M McIntyre; C M Hulette
Journal:  Acta Neuropathol       Date:  2001-12       Impact factor: 17.088

9.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

10.  Apolipoprotein E controls the risk and age at onset of Parkinson disease.

Authors:  Y J Li; M A Hauser; W K Scott; E R Martin; M W Booze; X J Qin; J W Walter; M A Nance; J P Hubble; W C Koller; R Pahwa; M B Stern; B C Hiner; J Jankovic; C G Goetz; G W Small; F Mastaglia; J L Haines; M A Pericak-Vance; J M Vance
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

View more
  12 in total

1.  Gender and Pathology-Specific Effect of Apolipoprotein E Genotype on Psychosis in Alzheimer's Disease.

Authors:  Julia Kim; Corinne E Fischer; Tom A Schweizer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

2.  Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.

Authors:  Steven P Cercy; Martin J Sadowski; Thomas Wisniewski
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

3.  Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease.

Authors:  Winnie Qian; Corinne E Fischer; Tom A Schweizer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

4.  Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

Authors:  Hirotake Uchikado; Wen-Lang Lin; Michael W DeLucia; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

5.  Stressful Life Events and Racial Disparities in Cognition Among Middle-Aged and Older Adults.

Authors:  Megan Zuelsdorff; Ozioma C Okonkwo; Derek Norton; Lisa L Barnes; Karen L Graham; Lindsay R Clark; Mary F Wyman; Susan F Benton; Alexander Gee; Nickolas Lambrou; Sterling C Johnson; Carey E Gleason
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Jennifer L Whitwell; David S Knopman; Mary M Machulda; Stephen D Weigand; Bradley F Boeve; Kejal Kantarci; Leonard Petrucelli; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-02-03       Impact factor: 17.088

7.  Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples.

Authors:  Willa D Brenowitz; C Dirk Keene; Stephen E Hawes; Rebecca A Hubbard; W T Longstreth; Randy L Woltjer; Paul K Crane; Eric B Larson; Walter A Kukull
Journal:  Neurobiol Aging       Date:  2017-01-30       Impact factor: 4.673

8.  APOE DNA methylation is altered in Lewy body dementia.

Authors:  Jessica Tulloch; Lesley Leong; Sunny Chen; C Dirk Keene; Steven P Millard; Andrew Shutes-David; Oscar L Lopez; Julia Kofler; Jeffrey A Kaye; Randy Woltjer; Peter T Nelson; Janna H Neltner; Gregory A Jicha; Douglas Galasko; Eliezer Masliah; James B Leverenz; Chang-En Yu; Debby Tsuang
Journal:  Alzheimers Dement       Date:  2018-03-12       Impact factor: 21.566

9.  APOE ε4 increases risk for dementia in pure synucleinopathies.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

10.  Age and apoE associations with complex pathologic features in Alzheimer's disease.

Authors:  Gregory A Jicha; Joseph E Parisi; Dennis W Dickson; Ruth H Cha; Kris A Johnson; Glenn E Smith; Bradley F Boeve; Ronald C Petersen; David S Knopman
Journal:  J Neurol Sci       Date:  2008-07-23       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.